Keros Therapeutics (NASDAQ:KROS) Now Covered by Scotiabank

Scotiabank assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a research report issued to clients and investors on Wednesday, Briefing.com reports. The firm set a “sector outperform” rating on the stock.

KROS has been the subject of several other reports. Truist Financial reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Bank of America decreased their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Oppenheimer assumed coverage on shares of Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target for the company. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Guggenheim assumed coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target for the company. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $90.63.

Keros Therapeutics Price Performance

Shares of KROS opened at $60.39 on Wednesday. Keros Therapeutics has a one year low of $27.02 and a one year high of $73.00. The company has a 50-day moving average of $52.45 and a two-hundred day moving average of $52.01. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -11.73 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The firm had revenue of $0.04 million during the quarter. During the same period last year, the firm posted ($1.27) EPS. Analysts anticipate that Keros Therapeutics will post -4.88 earnings per share for the current year.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics in the 2nd quarter worth $128,000. Ameritas Investment Partners Inc. lifted its position in Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares during the last quarter. Quest Partners LLC lifted its position in Keros Therapeutics by 23,945.0% during the 2nd quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock worth $220,000 after acquiring an additional 4,789 shares during the last quarter. XTX Topco Ltd acquired a new position in Keros Therapeutics during the 2nd quarter worth $228,000. Finally, Bayesian Capital Management LP acquired a new position in Keros Therapeutics during the 1st quarter worth $267,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.